Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAAXIA SINE in Vernal Keratoconjunctivitis
NCT00357019Phase 4Completed
- Sponsor
- Laboratoires Théa
- Start
- Apr 2001
- Modality
- Peptides, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of n-acetyl-aspartyl-glutamate in Vernal Keratoconjunctivitis (VKC) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Eosinophil Cationic Protein tear concentration at 28 days. Started Apr 2001; status: completed.
02
Drugs
n-acetyl-aspartyl-glutamate
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT00357019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357019.